Overview
- Adjusted EPS came in at €0.36 ($0.42), ahead of the $0.37 consensus.
- Quarterly sales totaled $5.03 billion with comparable sales up 3% as Diagnosis & Treatment grew 1%, Connected Care 5%, and Personal Health 11%.
- Adjusted EBITA rose to €531 million for a 12.3% margin, while income from operations declined to €330 million due to higher amortization.
- Cost measures delivered €222 million of quarterly savings within a three‑year €2.5 billion productivity program that targets €800 million in 2025.
- Full‑year targets were reaffirmed, including comparable sales growth of 1%–3%, an adjusted EBITA margin expected toward the upper end of 11.3%–11.8%, and free cash flow of €200–€400 million that factors in a €1.025 billion Respironics payout in Q1 2025, with shares up about 3% premarket.